Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American ...
In vivo proof-of-concept achieved in humanized mice and non-human primates (NHPs) using Gene Writers encapsulated in proprietary lipid nanoparticles (LNPs) targeting long-term hematopoietic stem cells (LT-HSCs) to rewrite the hemoglobin subunit beta (HBB) …